Biotech Values

[biomaven0]

Let me make one more comment on FLT3 in AML.

While it may be the case that pona works magic in this indication too, it is much more likely that this is an indication much different from CML or the ALK space. In other words, the drug will likely not be a magic bullet where you can tell in a Phase I whether you have an approvable drug or not. Instead you have to do the hard work of multiple trials, refining the dose, finding biomarkers and good drug combinations and so on. In other words, big pharma territory.

Peter